Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 2
2004 1
2007 2
2010 4
2011 1
2014 1
2015 2
2016 2
2017 3
2018 6
2019 3
2020 4
2021 3
2022 5
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma.
Kristensen NP, Heeke C, Tvingsholm SA, Borch A, Draghi A, Crowther MD, Carri I, Munk KK, Holm JS, Bjerregaard AM, Bentzen AK, Marquard AM, Szallasi Z, McGranahan N, Andersen R, Nielsen M, Jönsson GB, Donia M, Svane IM, Hadrup SR. Kristensen NP, et al. Among authors: draghi a. J Clin Invest. 2022 Jan 18;132(2):e150535. doi: 10.1172/JCI150535. J Clin Invest. 2022. PMID: 34813506 Free PMC article. Clinical Trial.
Acquired resistance to cancer immunotherapy.
Draghi A, Chamberlain CA, Furness A, Donia M. Draghi A, et al. Semin Immunopathol. 2019 Jan;41(1):31-40. doi: 10.1007/s00281-018-0692-y. Epub 2018 Jul 2. Semin Immunopathol. 2019. PMID: 29968044 Review.
Cancer immunotherapy in patients with brain metastases.
Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M. Caponnetto S, et al. Among authors: draghi a. Cancer Immunol Immunother. 2018 May;67(5):703-711. doi: 10.1007/s00262-018-2146-8. Epub 2018 Mar 8. Cancer Immunol Immunother. 2018. PMID: 29520474 Review.
Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Chen IM, Donia M, Chamberlain CA, Jensen AWP, Draghi A, Theile S, Madsen K, Hasselby JP, Toxværd A, Høgdall E, Lorentzen T, Wilken EE, Geertsen P, Svane IM, Johansen JS, Nielsen D. Chen IM, et al. Among authors: draghi a. Eur J Cancer. 2023 Feb;180:125-133. doi: 10.1016/j.ejca.2022.11.035. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36592507 Free article. Clinical Trial.
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
Tvingsholm SA, Frej MS, Rafa VM, Hansen UK, Ormhøj M, Tyron A, Jensen AWP, Kadivar M, Bentzen AK, Munk KK, Aasbjerg GN, Ternander JSH, Heeke C, Tamhane T, Schmess C, Funt SA, Kjeldsen JW, Kverneland AH, Met Ö, Draghi A, Jakobsen SN, Donia M, Marie Svane I, Hadrup SR. Tvingsholm SA, et al. Among authors: draghi a. J Immunother Cancer. 2023 Aug;11(8):e006847. doi: 10.1136/jitc-2023-006847. J Immunother Cancer. 2023. PMID: 37586765 Free PMC article.
Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Lee MH, Theodoropoulos J, Huuhtanen J, Bhattacharya D, Järvinen P, Tornberg S, Nísen H, Mirtti T, Uski I, Kumari A, Peltonen K, Draghi A, Donia M, Kreutzman A, Mustjoki S. Lee MH, et al. Among authors: draghi a. Cancer Res Commun. 2023 Jul 18;3(7):1260-1276. doi: 10.1158/2767-9764.CRC-22-0514. eCollection 2023 Jul. Cancer Res Commun. 2023. PMID: 37484198 Free PMC article.
37 results